Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivet Doses First Patient in Cohort 2 of Phase 1/2 GATEWAY Trial for Wilson Disease
Details : VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) gene therapy, which is being evaluated for the treatment of wilson disease.
Product Name : VTX-801
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Grants Orphan Drug Designation for Vivet's Gene Therapy for CTX
Details : VTX-806, an Adeno-associated viral (AAV) vector encoding human CYP27A1 is being investigating for the treatment of Cerebrotendinous Xanthomatosis (CTX).
Product Name : VTX-806
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Vivet Receives EUR 4.9 Million for Gene Therapy Development
Details : Vivet will use funds to develop VTX-806, aiming to halt or reverse disease progression in cerebrotendinous xanthomatosis patients.
Product Name : VTX-806
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivet Therapeutics’ VTX-801 Gets FDA Fast Track Designation for Wilson Disease
Details : VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.
Product Name : VTX-801
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the progr...
Product Name : VTX-803
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 04, 2021
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTX-803 is Vivet’s second gene therapy product to be granted Orphan Drug Designation. VTX-803 is currently under IND-enabling studies and initiation of clinical development is planned for the second part of 2021 in both the US and the EU.
Product Name : VTX-803
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 06, 2020
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable